Friess Associates LLC Exact Sciences Corp Transaction History

Friess Associates LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$72.5 - $100.68 $172,767 - $239,920	-2,383 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$90.24 - $124.05 $215,041 - $295,611	2,383 New	2,383 $227,000
Q3 2020 Nov 13, 2020	SELL	$72.92 - $102.01 $13 Million - $18.1 Million	-177,662 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$55.75 - $92.75 $5.72 Million - $9.51 Million	-102,581 Reduced 36.6%	177,662 $15.4 Million
Q1 2020 May 15, 2020	SELL	$37.9 - $104.44 $3.03 Million - $8.34 Million	-79,857 Reduced 22.18%	280,243 $16.3 Million
Q4 2019 Feb 14, 2020	BUY	$77.66 - $99.74 $28 Million - $35.9 Million	360,100 New	360,100 $33.3 Million
Q3 2019 Nov 14, 2019	SELL	$90.37 - $122.49 $8.87 Million - $12 Million	-98,110 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$56.04 - $82.66 $342,404 - $505,052	6,110 Added 6.64%	98,110 $6.19 Million
Q3 2018 Nov 14, 2018	SELL	$48.29 - $80.6 $9.49 Million - $15.8 Million	-196,550 Reduced 68.12%	92,000 $7.26 Million
Q2 2018 Aug 14, 2018	BUY	$37.84 - $69.96 $10.9 Million - $20.2 Million	288,550 New	288,550 $17.3 Million

673

162M

2.58M

2.19M

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $10.2B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

Get notified when there are updates to the investment portfolio of Friess Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Friess Associates LLC with notifications on news.